Trial Profile
Role of Pegylated Interferon in Combination With Direct Acting Antivirals (DAAs) to Cure Hepatitis C As Soon As Possible (ASAP) - Hepatitis C [ASAP-C]
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Daclatasvir; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ASAP-C
- 14 Mar 2019 Status changed from recruiting to completed.
- 05 Apr 2018 New trial record